What are Immix Biopharma, Inc.'s total assets?

Immix Biopharma, Inc. (IMMX) holds $95.8M in total assets, up 381.7% year over year.

How much debt does Immix Biopharma, Inc. have?

Immix Biopharma, Inc. carries $1.0M in total debt against $84.4M of shareholders' equity, a debt-to-equity ratio of 0.01.

How much cash does Immix Biopharma, Inc. have?

Immix Biopharma, Inc. holds $79.3M in cash and equivalents.

Can Immix Biopharma, Inc. cover its short-term obligations?

Its current ratio is 8.76 — current assets exceed current liabilities.

Where does Immix Biopharma, Inc.'s balance sheet data come from?

Every line is extracted from Immix Biopharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Immix Biopharma, Inc. IMMX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$93.93M+431%	$17.68M+1.0%	$17.51M+30.3%	$13.44M-23.8%
Short-term investments	$6.48M—	——	——	——
Prepaid expenses and other current assets	$3.01M-34.2%	$4.58M-34.7%	$7.01M+142%	$2.9M+459%
Income taxes receivable	$0-100%	$1.97M+68.4%	$1.17M+358%	$255.71K+894%
Total current assets	$101.24M+401%	$20.2M+2.1%	$19.79M+32.8%	$14.9M-18.1%
Property and equipment, net	$2.52M+44.9%	$1.74M+3,368%	$50.18K+1,310%	$3.56K-37.5%
Operating lease right-of-use assets	$966.92K+1,208,646,150%	$0.08—	——	——
Deferred tax assets	$1.13M+45.5%	$775.25K+606%	$109.86K-26.6%	$149.6K+41.5%
Other non-current assets	$20.42K0.0%	$20.42K—	——	$6.72K—
Total assets	$104.84M+357%	$22.95M+15.2%	$19.93M+33.7%	$14.91M-18.1%
Accounts payable	$5.44M+1.0%	$5.39M+276%	$1.43M+902%	$143.07K+0.1%
Accrued expenses	$942.16K+43.2%	$658.16K+13.9%	$577.85K+31.9%	$438.2K—
Operating lease liabilities, current	$139.34K+114%	$65.22K—	——	——
Total current liabilities	$10.11M+16.4%	$8.69M+133%	$3.72M+192%	$1.27M+530%
Operating lease liabilities, non-current	$933.63K-7.5%	$1.01M—	——	——
Operating Lease Liabilities (Total)	$1.07M-0.2%	$1.07M—	——	——
Total liabilities	$11.04M—	$0—	$0—	$0-100%
Common stock	200M0.0%	200M0.0%	200M0.0%	200M0.0%
Additional paid-in capital	$198.29M+124%	$88.37M+26.6%	$69.78M+36.4%	$51.16M+7.4%
Retained earnings	-$104.46M-39.2%	-$75.02M-40.5%	-$53.41M-40.6%	-$37.99M-27.7%
Accumulated other comprehensive income (loss)	$60.16K+5,797%	-$1.06K-101%	$134.67K+54.8%	$87.02K-30.6%
Treasury stock	$99.96K0.0%	$99.96K0.0%	$99.96K0.0%	$99.96K—
Total stockholders' equity	$93.8M+608%	$13.25M-19.2%	$16.41M+24.7%	$13.16M-26.8%
Total liabilities and stockholders' equity	$104.84M+357%	$22.95M+15.2%	$19.93M+33.7%	$14.91M-18.1%
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	$93.93M+431%	$17.68M+1.0%	$17.51M+30.3%	$13.44M-23.8%
Cash Cash Equivalents And Short Term Investments	$100.4M—	——	——	——
Other current assets	$150.72K+367%	$32.27K-27.6%	$44.58K-42.9%	$78.07K—
Deferred Tax Assets and Other Non-Current Assets	$20.42K0.0%	$20.42K—	——	$6.72K—
Net Investment in Lease	$966.92K+3.0%	$938.77K—	——	——
Net Operating Loss Carryforwards	$16.19K-99.4%	$2.53M+449%	$461.1K+113%	$216.42K+564%
Deferred contract costs	$93.63K—	——	$87.23K+1,197%	$6.72K—
Operating lease right-of-use assets	$966.92K-2.3%	$989.47K—	——	——
Other non-current assets	$20.42K0.0%	$20.42K—	——	$6.72K—
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$6.48M—	——	——	——
Operating Lease Right-of-Use Assets in Other Assets	$966.92K-2.3%	$989.47K—	——	——
Software and Technology Licenses, Net	$20.42K0.0%	$20.42K—	——	$6.72K—
Tax Credit Carryforward Valuation Allowance	$25.29M+60.4%	$15.76M+107%	$7.63M+126%	$3.38M+259%
Accrued Manufacturing Costs	$942.16K+43.2%	$658.16K+13.9%	$577.85K—	——
Accounts payable and other current liabilities (Note 11)	$9.97M+15.6%	$8.62M+132%	$3.72M+192%	$1.27M+791%
Compensation and benefits	$942.16K+43.2%	$658.16K+13.9%	$577.85K—	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	$158.33K+3.5%	$152.97K—	——	——
Operating Lease Liability Payments - 2025 (Lessee)	$169.6K+3.5%	$163.87K—	——	——
Lease Liability Payments - Due Year Two	$158.33K+3.5%	$152.97K—	——	——
Lease Liability Payments - Due Year Three	$163.87K+3.5%	$158.33K—	——	——
Lease Liability Payments - Due Year Four	$169.6K+3.5%	$163.87K—	——	——
Lease Liability Payments - Remainder of Fiscal Year	$218.97K+48.2%	$147.8K—	——	——
Operating Lease Liability Payments Due	$1.45M-5.3%	$1.53M—	——	——
Operating Lease Liability - Undiscounted Excess Amount	$377.68K-17.5%	$457.67K—	——	——
Operating Lease Liability Payments - 2026 (Lessee)	$163.87K+3.5%	$158.33K—	——	——
Operating Lease Liability Payments - 2027 (Lessee)	$175.54K+10.9%	$158.33K—	——	——
Operating Lease Liability Payments - 2028 (Lessee)	$169.6K+3.5%	$163.87K—	——	——
Other Accounts Payable and Accrued Liabilities	$331.8K+156%	$129.57K+28.3%	$101.01K-76.9%	$438.2K—
Total debt	$1.07M-0.2%	$1.07M—	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Authorized	5.3M+29.5%	4.1M+61.8%	2.5M+41.9%	1.8M+34.1%
Common Stock Shares Issued	53M+92.0%	27.6M+38.1%	20M+43.2%	14M+5.6%
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$5.3K+91.9%	$2.76K+38.1%	$2K+43.2%	$1.4K+5.6%
Number of Exercisable Options	3.2M+169%	1.2M-81.5%	6.4M+965%	603.3K-44.1%
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	5.3M+29.5%	4.1M+61.8%	2.5M+41.9%	1.8M+34.1%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	$3.83M+37.9%	$2.78M—	——	——
Share Price	$5.10—	——	——	——
Weighted Average Exercise Price of Exercisable Options	$2.06+5.1%	$1.96+11.4%	$1.76+14.3%	$1.54+15.8%
Weighted Average Exercise Price of Outstanding Options	$2.20+8.9%	$2.02+5.2%	$1.92-1.0%	$1.94+26.0%
Accrued Professional Services	——	$22.5K-41.8%	$38.64K—	——
Accrued Research And Development Expenses	$3.25M+34.3%	$2.42M+54.2%	$1.57M+2,633%	$57.5K—
Area Of Land	——	——	——	——
Cash and cash equivalents, end of period	$93.93M+431%	$17.68M+1.0%	$17.51M+30.3%	$13.44M-23.8%
Cash FDIC Insured Amount	$250K0.0%	$250K0.0%	$250K0.0%	$250K0.0%
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1	$1.32+85.9%	$0.710.0%	$0.71-82.7%	$4.11-34.2%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%
Common stock, shares issued (in shares)	$53.02M+92.0%	$27.61M+38.1%	$19.99M+43.2%	$13.96M+5.6%
Common Stock, Shares, Outstanding	$52.95M+92.3%	$27.54M+38.2%	$19.92M+43.4%	$13.89M+5.0%
Deferred offering costs	$93.63K—	$0-100%	$87.23K—	——
Deferred Tax Assets Amortization Of Capitalized Research And Development	$3.03M-45.9%	$5.6M+94.5%	$2.88M+183%	$1.02M—
Deferred Tax Assets Depreciation	$20.96K+97.3%	$10.62K—	——	——
Deferred Tax Assets Lease	$29.67K—	——	——	——
Deferred Tax Assets Tax Federal State Research Credit Carryforwards	$4.96M+96.0%	$2.53M—	——	——
Unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures	$3.83M+37.9%	$2.78M—	——	——
Grants receivable	$4.6M—	——	——	——
Grants Receivable Based On Achievement Of Milestones	$3.4M—	——	——	——
Income taxes receivable	$0-100%	$1.97M+68.4%	$1.17M+358%	$255.71K+894%
Lessee Operating Lease Liability Payments Due	$1.45M-5.3%	$1.53M—	——	——
Lessee Operating Lease Liability Payments Due Year Five And Thereafter	$564.34K-37.9%	$909.48K—	——	——
Lessee Operating Lease Liability Payments Due Year Four And Thereafter	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	$377.68K-17.5%	$457.67K—	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—
Prepaid Insurance	$179.9K+1,827%	$9.33K-96.5%	$263.93K-18.4%	$323.3K—
Prepaid Research And Development Expenses	$497.71K+5.3%	$472.51K+14.5%	$412.77K-47.9%	$792.13K—
Less: accumulated depreciation and amortization	$293K+520%	$47.26K+230%	$14.31K—	——
Total property, plant and equipment, gross	$2.84M+235%	$848.64K+1,216%	$64.5K—	——
Sale of stock, price per share (in dollars per share)	$0.01—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$5.26M+29.5%	$4.07M+61.8%	$2.51M+41.9%	$1.77M+34.1%
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number	$5.58M+142%	$2.31M0.0%	$2.31M+481%	$397.5K+8.6%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$2.2+8.9%	$2.02+5.2%	$1.92-1.0%	$1.94+26.0%
Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable	$3.19M+35.8%	$2.35M+89.1%	$1.24M+65.2%	$752.8K+55.4%
Share price (in dollars per share)	$5.1—	——	——	——
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1	$2.2+8.9%	$2.02+5.2%	$1.92-1.0%	$1.94+26.0%
Treasury stock, shares (in shares)	$72.36K0.0%	$72.36K0.0%	$72.36K0.0%	$72.36K—
Remainder of Fiscal Year 2024	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Immix Biopharma, Inc.'s total assets?: Immix Biopharma, Inc. (IMMX) holds $95.8M in total assets, up 381.7% year over year.
How much debt does Immix Biopharma, Inc. have?: Immix Biopharma, Inc. carries $1.0M in total debt against $84.4M of shareholders' equity, a debt-to-equity ratio of 0.01.
How much cash does Immix Biopharma, Inc. have?: Immix Biopharma, Inc. holds $79.3M in cash and equivalents.
Can Immix Biopharma, Inc. cover its short-term obligations?: Its current ratio is 8.76 — current assets exceed current liabilities.
Where does Immix Biopharma, Inc.'s balance sheet data come from?: Every line is extracted from Immix Biopharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.